Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CANF 
Can Fite Biopharma Ltd ADR (CANF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/11/2025: CANF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.78M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) 82969 | Beta 0.23 | 52 Weeks Range 0.98 - 4.69 | Updated Date 06/14/2025 |
52 Weeks Range 0.98 - 4.69 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1127.37% |
Management Effectiveness
Return on Assets (TTM) -53.18% | Return on Equity (TTM) -134.94% |
Valuation
Trailing PE - | Forward PE 2.97 | Enterprise Value 6328703 | Price to Sales(TTM) 20.44 |
Enterprise Value 6328703 | Price to Sales(TTM) 20.44 | ||
Enterprise Value to Revenue 9.39 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 12877200 | Shares Floating 3105367426 |
Shares Outstanding 12877200 | Shares Floating 3105367426 | ||
Percent Insiders - | Percent Institutions 1.21 |
Analyst Ratings
Rating 5 | Target Price 7.25 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Can Fite Biopharma Ltd ADR
Company Overview
History and Background
Can-Fite BioPharma Ltd. (founded 2000) is an Israeli biopharmaceutical company focused on developing novel treatments for liver, inflammatory, and metabolic diseases. The company develops orally bioavailable drugs with favorable safety and efficacy profiles.
Core Business Areas
- Liver Diseases: Development of Piclidenoson and Namodenoson for liver diseases like NASH and HCC.
- Inflammatory Diseases: Development of Piclidenoson for inflammatory conditions like psoriasis and rheumatoid arthritis.
- Metabolic Diseases: Investigating potential applications of its drug candidates in metabolic disorders.
Leadership and Structure
Dr. Pnina Fishman is the CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Piclidenoson: An A3 adenosine receptor agonist (A3AR) being developed for psoriasis and rheumatoid arthritis. Currently in late-stage clinical trials. Market share for psoriasis and rheumatoid arthritis treatments is fragmented among established pharmaceutical companies. Competitors include AbbVie (Humira, Skyrizi), Johnson & Johnson (Stelara), and Novartis (Cosentyx). Revenue is currently minimal as the drug is not yet approved.
- Namodenoson: An A3 adenosine receptor agonist (A3AR) being developed for hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH). Currently in clinical trials. The HCC and NASH markets are rapidly growing. Competitors include Bayer (Nexavar), Eisai (Lenvima) in HCC, and numerous companies developing NASH treatments. Revenue is currently minimal as the drug is not yet approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. There is a growing demand for innovative treatments for liver, inflammatory, and metabolic diseases.
Positioning
Can-Fite BioPharma Ltd. is a clinical-stage company focusing on A3AR agonists. Its competitive advantage lies in the potential of its drug candidates to address unmet medical needs with favorable safety profiles.
Total Addressable Market (TAM)
The TAM for NASH, HCC, psoriasis and Rheumatoid Arthritis is estimated to be in the tens of billions of dollars globally. Can-Fite is positioned to capture a portion of these markets if its clinical trials are successful and its drugs are approved.
Upturn SWOT Analysis
Strengths
- Novel A3AR agonist technology platform
- Strong patent portfolio
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Lack of commercialized products
- High risk of drug development failure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Growing demand for innovative treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- NVS
- GILD
Competitive Landscape
Can-Fite faces intense competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel A3AR agonist technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's pre-revenue stage.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Advancing clinical trials for Piclidenoson and Namodenoson, seeking partnerships, and exploring new indications.
Summary
Can-Fite Biopharma is a clinical-stage biopharmaceutical company with a novel A3AR agonist technology platform. Its success hinges on positive clinical trial results for its drug candidates, Piclidenoson and Namodenoson. The company faces significant financial risks and intense competition. Successful partnerships could accelerate development and commercialization, but clinical trial failures pose a major threat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Can Fite Biopharma Ltd ADR
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2012-11-06 | CEO and Chief Financial & Operating Officer Mr. Motti Farbstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.canfite.com |
Full time employees 5 | Website https://www.canfite.com | ||
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.